Cancer name Colon Cancer
Cancer Type COCA
Immunotherapy type Adoptive Cell Therapy
Treatment γδT cells
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature perforin
Official Symbol PRF1
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Flow cytometric detection showed that the following concentrations of TWS119, 0.5μM,1.0μM, 2μM and 4.0μM significantly upregulated the expression of perforin in a dose-dependent manner. However, 8.0μM of TWS119 obviously decreased the expression of perforin in γδT cells.
PMID 29104081
Title Wnt pathway activator TWS122 enhances the proliferation and cytolytic activity of human γδT cells against colon cancer